Drug intelligence / Profile preview

LAS40468

Development stage: Unknown
Lead developer: Almirall
Modality: Small Molecules
Administration: Inhalation

Overview

**LAS40468** was an Almirall investigational inhaled fixed-dose combination of the long-acting beta2-adrenergic agonist salmeterol and the inhaled corticosteroid fluticasone propionate, administered using the Genuair dry-powder inhaler. It was evaluated in a Phase 1 crossover study in adults with stable asthma against salmeterol/fluticasone propionate delivered by the Seretide Accuhaler. Salmeterol produces sustained bronchodilation through beta2-adrenergic receptor agonism, while fluticasone propionate activates the glucocorticoid receptor to suppress airway inflammation.

Other names: fluticasone propionate + salmeterolsalmeterol + fluticasone propionate

Targets

ADRB2 (β2)ADRB1 (β1)ADRB3 (β3)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on LAS40468.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAS40468.

Explore the full profile